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Despite recent developments in revascularisation, anti-platelet and anti-thrombotic
therapies, patients with acute coronary syndromes (ACS) remain at increased risk of
recurrent atherothrombotic events. Dual anti-platelet therapy comprising aspirin and
platelet P2Y12 receptor inhibition has become the cornerstone of therapy in ACS. However,
thrombin-mediated pathways, which contribute to platelet activation and are responsible
for the formation of fibrin clot, remain active following initial plaque rupture.
Recently, orally administered drugs which directly target thrombin, factor Xa or thrombin-
mediated platelet activation have been developed. Efficacy outcomes in trials of these novel
anti-thrombotic agents in ACS have yielded mixed results and their adoption in
clinical practice is currently hampered due to a penalty of increased bleeding. To date, the
direct Xa inhibitor rivaroxaban and the protease-activated receptor-1 antagonist atopaxar
have shown most promise and require further evaluation to determine their role in ACS
management.
& 2013 The Czech Society of Cardiology. Published by Elsevier Urban & Partner Sp.z o.o. All
rights reserved.
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Acute coronary syndromes (ACS) represent the most com-
mon clinical manifestation of cardiovascular disease and are
associated with both a short-term risk of morbidity and
mortality and a substantial risk of re-admission to hospital
within 6 months of the acute event [1]. Treatment costs
associated with ACS represent a major drain on healthcare
expenditure in economies across Europe [2]. The critical role
of coronary thrombus in the pathology of ACS provides the
rationale for intensive anti-platelet and anti-thrombotic ther-
apy as cornerstones of in-hospital management. The last two
decades have witnessed major advances in acute anti-
thrombotic and anti-platelet pharmacotherapy and recently
potent, rapidly acting oral anti-platelet agents have become
established for use in ACS. Despite these important advances,
however, around 10% of patients with ACS continue to
experience a recurrent athero-thrombotic event in the year
following the index ACS event [3–5]. Although routine treat-
ment with aspirin and a P2Y12 receptor inhibitor provides an
effective strategy for platelet inhibition following ACS,
thrombin-mediated effects including fibrin generation and
thrombin-mediated platelet activation may contribute to
recurrent athero-thrombotic events. Here we review the
recent evaluation of orally active factor Xa inhibitors, direct
thrombin inhibitors and protease activated receptor-1 (PAR 1)
inhibitors as potential strategies to further reduce recurrent
events in ACS.2. Mechanisms of action
Acute coronary syndromes (ACS) represent potentially life-
threatening consequences of atherosclerosis. Acute thrombosis
is typically induced by rupture or erosion of an atherosclerotic
plaque in the coronary circulation [6]. Exposure of sub-
endothelial matrix proteins and tissue factor initiate thrombosis
by activating platelets and factor X respectively (see Fig. 1).
Platelet-derived agonists including thromboxane A2 and adeno-
sine diphosphate (ADP) then further contribute to a feedback
cycle of platelet activation and aggregation. Factor Xa stimulates
the conversion of inactive prothrombin to the active serine
protease, thrombin. Thrombin then catalyses the conversion of
soluble fibrinogen to form insoluble fibrin strands which con-
tribute mechanical stability to the developing thrombus and
further amplify platelet activation through cleavage of the
protease-activate receptor 1 (PAR 1) on the platelet surface [7].
The rapid development of clot comprised of aggregated platelets
in a fibrin mesh leads to the clinical manifestation of acute
coronary syndrome through occlusion of the coronary artery
(typically in the case of ST segment elevation ACS) or by inducing
myocardial ischaemia through partial occlusion and micro-
embolisation (typically in the case of non-ST segment ACS).
The central role of thrombosis in the pathology of ACS argues forintensive inhibition of platelet activation and fibrin generation as
strategies to prevent continued thrombus generation in the
acute setting. Anti-platelet agents of proven efficacy in ACS
include aspirin [8], glycoprotein receptor inhibitors [9] and
P2Y12 inhibitors such as clopidogrel [4], prasugrel [3] or
ticagrelor [5]. Dual anti-platelet therapy (typically with aspirin
and an orally administered P2Y12 inhibitor) for up to one year
is recommended by the European Society of Cardiology follow-
ing ACS [10]. Thrombin generation in the acute setting is
combated by short-term use of parenterally administered anti-
coagulants, which may include unfractionated heparin, low-
molecular weight heparin [11], fondaparinux [12] or bivalirudin
[13]. However, it has been recognised for many years that pro-
coagulant factors may continue to be active for long periods
following ACS [14], suggesting that longer-term anti-thrombo-
tic therapy may be beneficial.3. Oral anti-thrombotics in ACS
An increased risk of recurrent ischaemic events after disconti-
nuation of unfractionated heparin or low-molecular weight has
been noted in ACS patients [15,16]. Following the observation
that increased levels of prothrombin fragments persist up to six
months after a coronary ischaemic event [14], several trials
investigated the possibility that long-term anti-coagulation with
vitamin K antagonists (e.g. warfarin) could prevent recurrent
atherothrombotic events following ACS. A comprehensive meta-
analysis of such trials demonstrated a significant reduction in
the incidence of recurrent ACS events and stroke with long-term
treatment with aspirin and warfarin compared to aspirin alone
[17]. However no associated decrease in mortality was apparent
and bleeding events were more than twice as common in those
receiving aspirin and warfarin in combination [17]. These trials
pre-dated the development of revascularisation with widespread
use of coronary artery stents in ACS. Additionally, concerns over
drug–drug interactions, variable bioavailability and the require-
ment for frequent INR monitoring limit the potential utility of
warfarin in this setting.
Recently, newer anti-thrombotic agents which may overcome
many of the limitations of warfarin or provide additional
strategies for platelet inhibition have been developed. These
agents comprise direct thrombin inhibitors, factor Xa inhibitors
and PAR 1 antagonists. Collectively these agents have stable
pharmacokinetic profiles, few food and drug–drug interactions
and do not require regular monitoring of anti-coagulant effect.
Several of the direct thrombin inhibitors and factor Xa inhibitors
were initially evaluated as anti-coagulants to prevent venous
thrombo-embolism or reduce the risk of stroke in non-valvular
atrial fibrillation and have been approved for clinical use in these
settings. Here we provide an overview of more recent phase II
and phase III trials in which novel anti-thrombotic drugs have
been evaluated in patients with ACS (summarised in Table 1).
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Fig. 1 – Schematic representation of activation of clotting pathways and thrombin-mediated platelet activation in acute
coronary syndrome. Sites of action of novel anti-thrombotic drugs on factor Xa, thrombin and protease-activated receptor 1
(PAR 1) are indicated.
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Thrombin is a critical player in both fibrin generation and
platelet activation following atherosclerotic plaque rupture.
Direct thrombin inhibitors inactivate soluble and fibrin-bound
thrombin and thereby limit thrombogenesis and reduce platelet
activation. Ximelagatran was an early oral direct thrombin
inhibitor, which demonstrated efficacy in reducing death, non-
fatal myocardial infarction and severe recurrent ischaemia in
ACS when used in combination with aspirin [18]. Further
evaluation of ximelagatran was abandoned in 2006 after con-
cerns arose over liver toxicity. However, the newer direct throm-
bin inhibitor dabigatran has subsequently been trialled in ACS.
4.1. Dabigatran
Dabigatran exelate is a competitive and reversible direct
thrombin inhibitor that binds to both free and fibrin-boundthrombin, thereby reducing conversion of fibrinogen into fibrin
and inhibiting thrombin-induced platelet aggregation. Dabiga-
tran is a pro-drug which is converted to its active metabolite by
plasma and liver esterases. Dabigatran has proved effective in
the prevention and treatment of venous thromboembolism
[19]. In non-valvular atrial fibrillation, the pivotal RE-LY trial
demonstrated that dabigatran 110mg twice daily was non-
inferior to warfarin and 150 mg twice daily was superior to
warfarin in reducing stroke or systemic embolisation [20].
The phase II dose-finding RE-DEEM trial investigated
escalating doses of dabigatran in 1861 patients with ACS
[21]. Patients with STEMI (60%) or NSTEMI (40%) and Z1
additional risk factor for a repeat event were randomised to
twice daily treatment with dabigatran 50 mg, 75 mg, 110 mg,
150 mg or placebo. 99% of patients received dual antiplatelet
therapy. The primary safety end point comprised major or
clinically relevant minor bleeding according to the Interna-
tional Society of Thrombosis and Haemostasis (ISTH)
Table 1 – Summary of key findings from phase III and phase II trials of novel anti-thrombotic drugs in acute coronary syndrome.
Study Year Sample
size
Follow up Drug Concomitant
treatment
Key findings
Direct thrombin inhibitors
RE-DEEM
(phase II)
2011 1861 6 Months Dabigatran 50 mg, 75 mg, 110 mg,
150 mg twice daily versus placebo
Dual antiplatelet Dose dependent increase in bleeding events.
No reduction in ischaemic events.
Factor Xa inhibitors
APPRAISE
(phase II)
2009 1715 6 Months Apixaban 2.5 mg twice daily Aspirin Apixaban showed dose related increase in
bleeding.
Apixaban 10 mg daily Clopidogrel Dose related trend towards reduction in
ischaemic events.Apixaban 10 mg twice daily
Apixaban 20 mg daily
Placebo
APPRAISE-2
(phase III)
2011 7392 8 Months Apixaban 5 mg twice daily vs.
placebo
Aspirin Apixaban 5 mg bd increased the number of major
bleeding events.
Clopidogrel
No significant reduction in recurrent ischaemic
events.
ATLAS ACS-
TIMI-46
(phase II)
2009 3491 6 Months Rivaroxaban 5 mg, 10 mg, 20 mg
daily vs. placebo
Stratum 1—aspirin
only
Significant increase in bleeding.
Stratum 2—aspirin
and clopidogrel
Reduced composite of death, MI, stroke.
ATLAS ACS-
TIMI-51
(phase III)
2012 15,526 13 Months Rivaroxaban 2.5 mg or 5 mg twice
daily vs. placebo
Dual antiplatelet Significant reduction of composite ischaemic end
point.
Increased risk of major bleeding and intracranial
haemorrhage.
RUBY-1
(phase II)
2011 1279 6 Months Darexaban 5 mg twice daily, 10 mg
once daily, 15 mg twice daily, 30 mg
once daily, 30 mg twice daily, 60 mg
once daily vs. placebo
Dual antiplatelet Dose related two- to four-fold increase in
bleeding.
No overall decrease in ischaemic events.
PAR 1 antagonists
Goto et al.
(phase II)
2010 117 60 Days Vorapaxar (20 mg loading then 1 mg
daily or 40 mg loading then 2.5 mg
daily) vs. placebo
Aspirin No difference in bleeding.
Ticlopidine Reduction in per-procedural MI.
TRACER
(phase III)
2012 12,944 502 Days Vorapaxar (40 mg loading then
2.5 mg daily) vs. placebo
Aspirin Increased major bleeding.
P2Y12 inhibitor Increased intra-cranial bleeding.
No difference in primary composite ischaemic
endpoint.
2010 504 12–24 Weeks Aspirin No difference in bleeding.
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c o r e t v a s a 5 5 ( 2 0 1 3 ) e 1 1 7 – e 1 2 5 e121definition [22] over 6-months. Dabigatran therapy was asso-
ciated with 2–4 fold, dose-dependent increased risk of bleed-
ing with the primary endpoint occurring in 3.5%, 4.3%, 7.9%
and 7.8% of patients receiving the 50, 75, 110 and 150 mg
twice daily doses respectively—compared to 2.2% receiving
placebo (Po0.001). Although the study was not powered for
efficacy, no significant reduction in ischaemic events was
apparent in patients receiving dabigatran. The composite of
cardiovascular death, myocardial infarction and stroke
occurred in 4.6%, 4.9%, 3.0% and 3.5% of patients receiving
the 50, 75, 110 and 150 mg twice daily doses
respectively—compared to 3.8% in the placebo group.
Dabigatran has not been evaluated further in a phase III
trial in ACS. However, potential safety concerns have
emerged following recognition of a small increased risk of
myocardial infarction in patients with atrial fibrillation
receiving dabigatran compared to warfarin in the RE-LY trial
[20] and an increased risk of acute coronary events in patients
receiving dabigatran reported in a recent meta-analysis [23].5. Factor Xa inhibitors
Activation of factor X plays a critical role in activation of the
clotting cascade following atherosclerotic plaque rupture.
Several selective, orally active factor Xa inhibitors have been
developed and recently evaluated in ACS.
5.1. Apixaban
Apixaban is an orally active, selective, direct-acting, factor Xa
inhibitor. Apixaban was demonstrated to reduce the incidence
of venous thromboembolism in patients undergoing orthopae-
dic surgery [24] and to prevent thromboembolic events in
patients with atrial fibrillation [25]. Apixaban has a half-life of
12 h and is eliminated predominantly through non-renal
mechanisms. In the phase II APPRAISE trial, 1715 subjects
within 7 days of an ACS and with Z1 additional risk factor for
recurrent events were randomised to placebo or to one of four
doses of apixaban (2.5mg twice daily, 10 mg once daily, 10mg
twice daily or 20mg once daily) [26]. The two treatment arms
with the higher doses were discontinued early because of
excess bleeding. The primary outcome of ISTH major and
clinically relevant non-major bleeding occurred in 3.0% of
patients receiving placebo, 5.7% of patients receiving apixaban
2.5 mg twice daily and 7.9% of patients receiving apixaban
10mg once daily. There was no statistically significant differ-
ence in ischaemic end-points between patients receiving
apixaban (7.6% and 6.0%) or placebo (8.7%).
The 10 mg daily dose of apixaban was selected for a phase
III trial for the prevention of recurrent events in ACS.
APPRAISE-2 randomised high-risk ACS patients to placebo
or apixaban 5 mg twice daily in addition to dual anti-platelet
therapy with aspirin and clopidogrel [27]. The trial was
terminated prematurely after recruitment of 7392 patients
because of an increase in major bleeding events with apix-
aban in the absence of a reduction in recurrent ischaemic
events. Over a median follow-up of 241 days, the primary
outcome of cardiovascular death, myocardial infarction, or
ischaemic stroke occurred in 279 of the 3705 patients (7.5%)
c o r e t v a s a 5 5 ( 2 0 1 3 ) e 1 1 7 – e 1 2 5e122assigned to apixaban (13.2 events per 100 patient-years) and
in 293 of the 3687 patients (7.9%) assigned to placebo (14.0
events per 100 patient-years) (hazard ratio with apixaban,
0.95; 95% confidence interval [CI], 0.80–1.11; P¼0.51). The
primary safety outcome of major bleeding according to the
Thrombolysis in Myocardial Infarction (TIMI) definition
occurred in 46 of the 3673 patients (1.3%) who received at
least one dose of apixaban (2.4 events per 100 patient-years)
and in 18 of the 3642 patients (0.5%) who received at least one
dose of placebo (0.9 events per 100 patient-years; hazard ratio
with apixaban, 2.59; 95% CI, 1.50–4.46; P¼0.001).
5.2. Rivaroxaban
Rivaroxaban is another selective, direct-acting factor Xa inhi-
bitor which is effective in the prevention and treatment of
venous thromboembolism [28] and in the prevention of stroke
and systemic embolisation in non-valvular atrial fibrillation
[29]. In the ATLAS ACS-TIMI-46 phase II dose-finding trial or
rivaroxaban, 3491 high-risk patients with ACS were assigned at
their physician’s discretion to aspirin alone (stratum 1) or to
aspirin plus a thienopyridine (stratum 2) [30]. In each stratum,
patients were randomised to placebo or rivaroxaban 5mg,
10 mg or 20 mg daily (administered once daily or in two divided
doses). Rivaroxaban was associated with a significant increase
in bleeding in both stratum 1 and stratum 2. The overall risk of
clinically significant bleeding with rivaroxaban vs. placebo
increased in a dose-dependent manner (hazard ratios [HRs]
2.21 [95% CI 1.25–3.91] for 5 mg, 3.35 [2.31–4.87] for 10 mg, 3.60
[2.32–5.58] for 15 mg, and 5.06 [3.45–7.42] for 20 mg doses;
po0.0001). Rivaroxaban did not reduce the primary efficacy
endpoint (a composite of death, myocardial infarction, stroke,
or severe recurrent ischaemia requiring revascularisation dur-
ing 6 months). However, rivaroxaban did reduce the secondary
efficacy end point of death, MI or stroke compared to placebo
(3.9% vs. 5  5%; HR 0.69, [95% CI 0.50–0.96], P¼0.0270).
The findings of this study led to the larger phase III ATLAS
ACS 2-TIMI 51 trial, in which two doses of rivaroxaban (5mg/day
or 10mg/day) were selected for evaluation [31]. In ATLAS ACS 2-
TIMI 51, 15,526 patients with ACS were randomised 1:1:1 to
rivaroxaban 2.5mg twice daily, rivaroxaban 5mg twice daily or
placebo in addition to aspirin and a P2Y12 inhibitor. Over a
median follow up of 31 months, both doses of rivaroxaban
decreased the primary efficacy end point of death from cardio-
vascular causes, myocardial infarction or stroke compared to
placebo (2.5mg dose 9.1% vs. 10.7%, HR 0.84, 95% CI 0.72–0.97;
5mg dose 8.8% vs. 10.7%, HR 0.85, 95% CI 0.73–0.98). However,
rivaroxaban increased the rates of major bleeding not related to
coronary-artery bypass grafting (2.1% vs. 0.6%, Po0.001) and
intracranial haemorrhage (0.6% vs. 0.2%, P¼0.009), without a
significant increase in fatal bleeding (0.3% vs. 0.2%, P¼0.66). The
twice-daily 2.5-mg dose of rivaroxaban reduced the rates of
death from cardiovascular causes (2.7% vs. 4.1%, P¼0.002) and of
death from any cause (2.9% vs. 4.5%, P¼0.002).
5.3. Darexaban
Darexaban is a further direct inhibitor of factor Xa which has
been evaluated in ACS. Darexaban is a pro-drug which rapidly
absorbed from the gut and converted to its active metabolite. Itreaches maximum plasma levels at 1–1.5 h post-dose and has
a terminal half-life of 14–18 h. Darexaban demonstrates pre-
dictable pharmacokinetics and pharmacodynamics. Darexa-
ban has minimal interaction with food and, unlike the other
available direct factor Xa inhibitors, has no important interac-
tions with CYP3A4/P-glycoprotein inhibitors and inducers [32].
Darexaban has been evaluated for prevention of venous
thromboembolism and for the prevention of stroke in non-
valvular atrial fibrillation. In ACS, the phase II RUBY trial
investigated 1279 patients in a 26-week, multi-centre, double-
blind, randomized, parallel-group study [33]. Patients with
recent high-risk non-ST-segment elevation ACS or ST-
segment elevation ACS were randomised to one of six
darexaban regimens or placebo in addition to dual antiplate-
let therapy. A dose-dependent increase in bleeding events
was observed in the darexaban active treatment arms (pooled
HR 2.2275, 95% CI 1.13–4.60). The main efficacy outcome (a
composite of death, stroke, myocardial infarction, systemic
thromboembolism, and severe recurrent ischaemia) was not
reduced by darexaban, although the study was under-
powered to assess efficacy. The data were not sufficiently
encouraging to progress to a phase III trial and it is unlikely
that darexaban will be further examined in the context
of ACS.6. PAR 1 antagonists
Cleavage of platelet surface PAR 1 by fibrin promotes platelet
activation and the release of the pro-aggregatory mediators
adenosine diphosphate, serotonin and thromboxane A2. The
thrombin-induced platelet activation mediated through PAR 1
is thought to contribute to coronary thrombosis and has
prompted the recent evaluation of PAR 1 inhibitors as
potential therapeutic agents in ACS.
6.1. Vorapaxar
Vorapaxar is an orally active compound which mediates
selective and reversible inhibition of PAR 1. Vorapaxar has
high bioavailability associated with a long plasma half-life.
Elimination is predominantly through metabolism by hepatic
CYP3A4 enzymes, raising the possibility of interaction with
CYP3A4 activators and inhibitors. Voropaxar has been eval-
uated in three phase II studies in patients with coronary
artery disease. In the TRA-PCI study, vorapaxar in addition to
aspirin and clopidogrel was evaluated in patients undergoing
non-urgent PCI [34]. A reduction in major adverse cardiovas-
cular events was noted in the absence of an increased
bleeding risk. In a subsequent phase II study in ACS, 117
patients with ACS scheduled for PCI were randomised to
vorapaxar (20 mg or 40 mg loading dose followed by 1 mg or
2.5 mg maintenance dose once daily) or placebo for 60 days
[35]. Incidence of bleeding events was similar in placebo and
vorapaxar-treated groups. A significant reduction of bio-
chemically detected peri-procedural myocardial infarction
was associated with vorapaxar administration although no
clinically significant adverse ischaemic events were present
in either placebo or vorapaxar treated groups. In the much
larger TRACER study, 12,944 patients with non-ST segment
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loading and 2.5 mg daily maintenance dose) or placebo in
addition to aspirin and a P2Y12 inhibitor [36]. The trial was
stopped early after a safety review identified an unacceptable
increase in bleeding in vorapaxar treated patients. Rates of
moderate and severe bleeding were 7.2% in the vorapaxar
group and 5.2% in the placebo group (hazard ratio, 1.35; 95%
CI, 1.16–1.58; Po0.001). Intracranial haemorrhage occurred in
1.1% and 0.2%, respectively (HR, 3.39; 95% CI, 1.78–6.45;
Po0.001). The primary end point (death from cardiovascular
causes, myocardial infarction, stroke, recurrent ischaemia
with rehospitalization, or urgent coronary revascularization)
was not significantly different in patients receiving vorapaxar
vs. patients receiving placebo (Kaplan–Meier 2-year rate,
18.5% vs. 19.9%; HR, 0.92; 95% CI, 0.85–1.01; P¼0.07). However,
the composite of death from cardiovascular causes, myocar-
dial infarction, or stroke occurred less commonly in the
vorapaxar group vs. the placebo group (14.7% and 16.4%,
respectively; HR, 0.89; 95% CI, 0.81–0.98; P¼0.02).
6.2. Atopaxar
Atopaxar is an orally active, reversible PAR 1 inhibitor with high
bioactivity, though with a shorter half-life than vorapaxar. It is
also metabolised via the CYP3A4 enzyme system. Two small
phase II trials of atopaxar conducted in Japan (reported together
as J-LANCELOT) demonstrated effective platelet inhibition in the
absence of increased risk of bleeding in patients with ACS or
high risk coronary artery disease [37]. Dose-dependent increases
in liver function abnormalities and corrected QT interval were
observed in atopaxar-treated patients. Atopaxar has subse-
quently been evaluated in a larger international phase II study
in ACS. In LANCELOT-ACS, 603 patients with non-ST segment
elevation ACS were randomised to receive one of three doses of
atopaxar (400-mg loading dose followed by 50, 100, or 200mg
daily) or placebo in addition to aspirin and a P2Y12 inhibitor [38].
The primary endpoint, the incidence of Clopidogrel in Unstable
Angina to Prevent Recurrent Events (CURE) major or minor
bleeding, did not differ significantly between the atopaxar and
placebo groups (3.08% vs. 2.17%, respectively; P¼0.63). A signal
for efficacy was provided by the finding that atopaxar signifi-
cantly reduced ischaemia on continuous ECGmonitoring (Holter)
at 48 h compared with placebo (relative risk, 0.67; P¼0.02). This
did not translate into a significant reduction in the incidence of
cardiovascular death, myocardial infarction, or stroke (5.63% in
the placebo group vs. 3.25% in the combined atopaxar group
(P¼0.20)). However, the study was underpowered to detect
clinical efficacy in reducing ischaemic events. Transient dose-
dependent transaminase elevation and relative QTc prolongation
were observed in patients receiving the highest doses of ato-
paxar. Collectively, the findings of reduced Holter-detected
ischaemia in the absence of an increased bleeding risk in
LANCELOT-ACS are encouraging and support the further evalua-
tion of atopaxar in larger studies in patients with ACS.7. Summary and future directions
Novel oral anti-thrombotic drugs target complementary path-
ways to those addressed by the current standard combinationof aspirin and a P2Y12 inhibitor in ACS, and offer a plausible
strategy to reduce recurrent ischaemic events. However, effi-
cacy outcomes in recent clinical trials of factor Xa inhibitors,
direct thrombin inhibitors and PAR 1 inhibitors in ACS are
mixed, even within the same class of compound, and the
increased bleeding risk observed in many of the trials remains
a major concern. Darexaban and apixaban were both asso-
ciated with increased bleeding in ACS and darexaban has been
withdrawn from further development. Dabigatran is yet to be
evaluated in a phase III clinical trial in ACS; however the signal
of increased risk of myocardial infarction in the RE-LY study in
non-valvular atrial fibrillation represents cause for concern in
this context. Both apixaban and the PAR 1 inhibitor vorapaxar
increased major bleeding in ACS without any evidence of
reduction in cardiovascular ischaemic events.
To date, rivaroxaban and atopaxar represent the com-
pounds showing most promise for risk reduction in ACS
whilst maintaining an acceptable safety profile. In ATLAS
ACS 2-TIMI 51, rivaroxaban demonstrated an overall 16%
decrease in recurrent ischaemic events and a 32% decrease
in overall mortality at the lower dose evaluated (2.5 mg) [31].
However, this efficacy benefit comes with the penalty of a
significant increase in major bleeding events with rivaroxa-
ban overall. The PAR 1 inhibitor atopaxar improved the
surrogate marker of Holter-detected ischaemia in
LANCELOT-ACS without increasing the risk of significant
bleeding [38], but remains to be evaluated in a large-scale
trial to assess its potential to reduce clinical adverse events.
Several factors may contribute to the disparate results
from these trials of novel anti-thrombotic drugs in ACS and
are pertinent to their interpretation. In particular, considera-
tion of differences in patient selection, dosing and definition
of bleeding events are relevant to assessing the balance
between clinical efficacy and bleeding risk in the trials. The
risk profile of trial participants is likely to impact both on the
potential for a novel compound to demonstrate efficacy in
reducing ischaemic events and on its susceptibility to
increase bleeding. Baseline risk differed substantially
between the trials of novel anti-thrombotic drugs in ACS.
For example, APPRAISE-2 enroled older, higher risk ACS
patients with at least two additional risk factors [26], whereas
patients in ATLAS-ACS-2 were not required to have additional
risk factors and potential participants with previous intra-
cranial haemorrhage or stroke were excluded [31]. Bleeding is
a major concern with novel anti-thrombotic drugs, not least
because, unlike warfarin, effective strategies to reverse the
anti-coagulant effects in serious bleeding are not readily
available [39]. Additionally, disparate definitions of bleeding
events used in the recent trials render it difficult to satisfac-
torily compare haemorrhagic outcomes between trials.
In addition to baseline population risk, the dose of novel
anti-thrombotic drug selected for ACS trials is likely to be of
critical importance in negotiating the balance between clinical
efficacy and bleeding. This is especially pertinent in the context
of dual anti-platelet therapy which itself increases the risk of
bleeding complications. What is not yet clear is whether it is
indeed feasible to achieve additional reduction of recurrent
cardiovascular events in ACS through the use of novel anti-
coagulants without incurring a penalty of increased bleeding. In
future, it may be necessary to evaluate selective use of novel
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recurrent ischaemic events rather than ‘all-comers’ with ACS.
However, patients identified as being at high risk of ischaemic
events by available risk scores (e.g. GRACE, PURSUITor TIMI) are
often also at high risk of bleeding. Newer bleeding risk scores in
ACS [40] may be useful to weigh the risks and benefits in
individual patients. It is reassuring that recent data do not
suggest increasing incidence of serious bleeding over time in
real-world ACS registries [41,42], suggesting that physicians
may already be using more aggressive anti-thrombotic drugs
selectively in their patients. Some commentators have pro-
posed an optimal dose of anti-thrombotic, or a ‘sweet-spot’, at
which clinical efficacy may be attained with minimum haemor-
rhagic exposure [43]. It is noteworthy that the dose of apixaban
employed in the APPRAISE-2 trial is the same as that used for
thromboembolic prophylaxis in atrial fibrillation. In contrast,
the dose of rivaroxaban used in ATLAS ACS 2-TIMI 51 is one
quarter of that used in atrial fibrillation. Onemay speculate that
future trials seeking to achieve a consistent low-level anti-
thrombotic effect may be able to facilitate cardiovascular event
reduction with an acceptable bleeding risk in ACS patients
receiving concomitant intensive anti-platelet therapy.
Uncertainty remains over how novel anti-coagulants will
be positioned in the future therapeutic armamentarium for
ACS. The arena of anti-platelet therapy is rapidly evolving
and the landmark TRITON and PLATO studies have provided
a strong rationale for the use of newer P2Y12 inhibitors
prasugrel and ticagrelor, rather than clopidogrel, in ACS
[3,5]. This change has been reflected in the recent European
Society of Cardiology Guidelines for the management of non-
ST elevation myocardial infarction [10]. Demonstration in
PLATO of reduced all-cause mortality in ACS patients with
an acceptable overall bleeding risk [5] is likely to herald more
widespread use of ticagrelor in particular. Most of the recent
trials of novel anti-thrombotic drugs in ACS have been
undertaken on a background of aspirin and clopidogrel dual
anti-platelet therapy. Whether the novel anti-thrombotics
have a role in patients receiving newer generation P2Y12
inhibitors remains to be evaluated. It is feasible that novel
anti-thrombotic drugs could prove complimentary by antag-
onising thrombin-mediated platelet activation. In particular,
atopaxar may offer the opportunity to inhibit thrombin-
mediated platelet activation through PAR 1 antagonism with-
out interfering with thrombin-mediated fibrin generation. It
remains to be seen whether the neutral effect on bleeding
risk of atopaxar in phase II trials can be maintained whilst
demonstrating clinical efficacy in larger studies.
In conclusion, patients sustaining an ACS remain exposed
to an unacceptable risk of subsequent recurrent events despite
revascularisation and dual anti-platelet therapy. Novel
approaches targeting fibrin generation and thrombin-
mediated platelet activation represent important opportunities
to reduce recurrent ischaemic events in ACS. The recent
development of selective orally-administered direct thrombin
inhibitors, factor Xa inhibitors and PAR 1 antagonists has gone
some way in addressing this unmet need. However, mixed
evidence of clinical efficacy and unacceptable risks of bleeding
encountered with several of these agents have proved to be
disappointing. The direct Xa inhibitor rivaroxaban and the PAR
1 antagonist atopaxar have demonstrated the mostencouraging results to date and warrant further evaluation in
the changing environment of ACS management.
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